Similarly, an ORR of 40% and an mPFS of 6.6 months were obtained in patients with advanced NSCLC that had progressed after treatment with PD-1 inhibitors combined with platinum-based chemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.